Nocardiosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Nocardiosis}} {{CMG}} ==Overview== ==Future or Investigational Therapies== A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has..." |
No edit summary |
||
| Line 10: | Line 10: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Disease]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Bacterial diseases]] | |||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Revision as of 21:41, 28 November 2012
|
Nocardiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Nocardiosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Nocardiosis future or investigational therapies |
|
Risk calculators and risk factors for Nocardiosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has shown promise for treatment of infections not responding to standard antimicrobial treatments. Application of newer molecular diagnostic and subtyping methods may assist in earlier diagnosis.